By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

AbbVie will commit "less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+11.7% vs. -2.2%). The ...

Shares of AbbVie Inc. ABBV slid 1.47% to $171.35 Wednesday, on what proved to be an all-around positive trading session for ...